Status:
RECRUITING
Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder
Lead Sponsor:
Sanjay R Patel
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Central Sleep Apnea Comorbid With Opioid Use
Eligibility:
All Genders
18-100 years
Phase:
PHASE2
Brief Summary
Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic tr...
Detailed Description
Medications used to treat opioid use disorder (MOUD) such as methadone and buprenorphine have been found to cause central sleep apnea (CSA), but the clinical ramifications are unclear. It has been hyp...
Eligibility Criteria
Inclusion
- Patients on Medication for Opioid Use Disorder (MOUD) with central sleep apnea.
Exclusion
- Sleep-related Hypoventilation.
- Other causes of Central Sleep Apnea besides Opioid Use.
- Pregnancy.
- Contraindications for Acetazolamide.
Key Trial Info
Start Date :
September 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2028
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06521476
Start Date
September 30 2025
End Date
February 1 2028
Last Update
October 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213